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Copyright © 2008 JCBN Summary Quality of ulcer healing (QOUH) is defined as ideal ulcer healing featuring with
the fine granular ulcer scar, high functional restoration and the resistance to recurrence. This
study was designed to compare the rates of QOUH achievement in rat gastric ulcer model
between acid suppressant treated group and gastroprotectant treated group accompanied with
elucidations of molecular mechanisms. Serosal injection of acetic acids for generating gastric
ulcer and intraperitoneal (ip) injection of recombinant interleukin 1-beta (IL-1β) for recurring
healed ulcer was done in SD rats. The 72 rats were divided into three groups according to
treatment as follows; Group I, no further treatment, Group II, 8 weeks treatment of
omeprazole, and Group III, 8 weeks of gastroprotectant treatment. IL-1β was administered for
ulcer recurrence after 28 weeks of acetic acid injection. At four weeks after gastric ulcero-
genesis, 58.3% (7/12) of active gastric ulcer were converted to healing stage in Group III, but
16.7% (2/12) in Group II and none in Group I, for which significant levels of epidermal growth
factor, mucin, and pS2/trefoil peptide1 were contributive to these accelerated healings of
Group III. ip injections of rIL-1β (200 µg/kg) at 28 weeks after acetic acid injection led to
100% of ulcer recurrence in Group I and 75.0% in Group II, but only 16.7% of Group III
rats showed ulcer recurrence. Significantly attenuated levels of inflammatory cytokines
including IL-2, transforming growth factor-alpha (TNF-α), cyclooxygenase-2 (COX-2), nitro-
tyrosine were responsible for the resistance to ulcer recurrence in Group III. Conclusively,
gastroprotectant might be prerequisite in order to achieve ideal QOUH through significant
inductions of remodeling.
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Introduction
Since the discovery of hydrochloric acid and pepsin in the
stomach, the question that “Why does the stomach not digest
itself?”, “How does the gastric mucosa preserve its normal
integrity against noxious materials that are secreted?”, and
“How does the stomach resist against damaging Helico-
bacter pylori (H. pylori) or non-steroidal anti-inflammatory
drugs (NSAIDs)?” has persisted [1–3], after which the
identification of the presence of “gastric mucosal barrier”
was imposed [4]. When the barrier is broken by the aggres-
sive offensive factors, the gastric mucosa allows a back
diffusion of gastric acid into the mucosal layers, leading to
mucosal damages. Therefore, acid suppressants had been
gold standard in the treatment of gastric ulcer with consider-QOUH Feasible only with Gastroprotectant
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able rates of healing and achievements of symptoms relief
in accordance with the eradication of H. pylori, if associated
[5, 6].
However, because the considerable portion of patients
suffered from recurrence or complication in spite of mainte-
nance medications or even after complete resolution [7],
many investigators had performed diverse studies revealing
the significance of gastric defense system to overcome these
limitations of acid suppressant treatment. Several kinds of
gastroprotectants are available in clinic, including sucral-
fate, rebamipide, misoprostol, ecabet sodium, sofalcone,
DA-9601 (ethanol extracts of Artemisia asiatica), etc.,
achieving the several lines of clinical efficacy [8–11].
Ulcer healing is a dynamic process of filling the mucosal
defect with epithelial and connective tissue cells, for which
complex biological responses including cell proliferation,
migration, differentiation, regeneration, active angiogenesis,
and extracellular matrix deposition are required [6, 7, 12,
13]. Biological molecular processes for ulcer healing are
comprised of inflammation, cell migration, mitosis, and
remodeling, all of which are associated with the active
synthesis and release of several peptide growth factors at
the site of injury such as epidermal growth factor (EGF),
transforming growth factor-alpha (TGF-α), TGF-β, fibro-
blast growth factor (FGF) as well as trefoil peptide [14, 15].
The complex interaction of these proteins led to rapid
restitution process composed of re-epithelialization, restora-
tion of muscular components, angiogenesis, and tissue
remodeling [16, 17].
The achievement of quality of ulcer healing (QOUH),
ideal ulcer healing, is thought to be prostaglandin (PG)-
dependent because exogenous PGs could reverse events
involved in ulcer recurrence, inflammatory response, retarded
ulcer healing, and defective angiogenesis [18]. Even though,
in clinic, chromoscopy is able to detect and differentiate
whether the pattern of the gastric ulcer is flat on nodular [17,
19, 20], still there was limited report clearly showing the
objective rate of QOUH achievement after either acid
suppressant or gastroprotectant treatment, more scarse in
elucidating the underlying molecular mechansism. Our
study was designed to compare the healing efficiency and
the resistance of ulcer recurrence between acid suppressant
and gastroprotectant treatment in rat model of acetic acid-
induced gastric ulcer and explored the underlying molecular
mechanisms to explain the difference according to treatment
plan. Omeprazole was administered as acid suppressant and
DA-9601 was used as gastric cytoprotectant. DA-9601 used
in the current study was demonstrated to possess cyto-
protective actions in various experimental models, including
ethanol-induced gastric mucosal damage, reflux esophagitis,
and trinitrobenzosulfonic acid (TNBS)-induced colitis, of
which mechanisms were stimulation of mucus, PG,
glutathione and antioxidative actions [11, 21–24].
Materials and Methods
Animals
Sprague-Dawley rats with a body weight of 200 g–250 g
were used in the experiments. Total 72 SD rats were used for
the current experiment and were fed standard laboratory
chow and tap water and kept in the room with controlled
temperature (22 ± 1°C), humidity (50%), and light cycle
(12 h light/12 h dark). The rats were fasted for 18 h before
injection of acetic acid to the stomach. During fasting, all
animals were kept in mesh-bottom cages to prevent
coprophagy.
Induction of acetic acid-induced gastric ulcer
Under the anesthesia with ketamine, the laparotomy was
done for acetic acid (40 µl, 10% vol/vol), which was injected
to the subserosa of the stomach with micro-syringe to induce
gastric ulcer. We tried to induce gastric ulcer in the same
area of each stomach in the mid-fundus between the two
branches of the main arterial vessel. The abdomen was
sutured and the rats were returned to their cages. After
operation, the rats were fasted for 48 h more with the supply
of intravenous fluid infusion through carotid cannulation
catheter and were fed normally thereafter (Fig. 1). To
determine the size of ulcers and stages after 4 weeks or 24
weeks after acetic acid injection, animals were killed with an
overdose of ether and their stomachs were removed. The
stomachs were opened along the greater curvature and
rinsed with cold saline. Then the stomachs were pinned to a
cork board and then inflated, and the areas (mm2) of the
ulcers were determined under a dissecting macroscope
(Olympus, Tokyo, Japan) and the classification of ulcer
stage was determined based on the classification of Sakita
and Miwa [25] as follows; A stage (active stage, A1, the
surrounding mucosa is edematously swollen and no
regenerating epithelium is seen. A2, the surrounding edema
has decreased, the ulcer margin is clear, and slight amount of
regenerating epithelium is seen in the ulcer margin), H stage
(healing stage, H1, the white coating is becoming thin and
the regenerating epithelium is expanding into the ulcer base.
The gradient between ulcer margin and the ulcer floor is
becoming flat. The diameter of the mucosal defect is about
one half to two thirds that of A1; H2, the defect is smaller
than in H1 and the regenerating epithelium covers most of
ulcer floors and the area of white coating is about a quarter
to one third that of A1) and S stage (scarring stage, S, the
regenerating epithelium completely covers the floor of
ulcer. The white coating has disappeared. Upon close
observation, many capillaries can be seen, which is called
“red scar” (S1), which become white scar with the reduction
of redness, called “white scar” (S2).T.Y. Oh et al.
J. Clin. Biochem. Nutr.
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Experimental group assignment
The 72 rats were grouped in to three as follows; Group I
(n = 24) is rats without any treatment at all, natural healing
group, Group II (n = 24) is rats treated with omeprazole
10 mg/kg intaperitoneally for 8 weeks, and Group III
(n = 24) is rats treated with diet pellet containing 100 mg/kg
of DA-9601, which is ethanol extract of Artemisia asiatica
showing anti-inflammatory, antioxidative, and PG inducing
actions. Half of these rats in each group were killed at 4
weeks after acetic acid injection and the remaining 36 rats
were sacrificed at 28 weeks 2days after interleukin-1β
(IL-1β) injection.
Gastric ulcer recurrence with intraperitoneal injection of
recombinant IL-1β
As a preliminary study to document that 28 weeks was
enough for natural healing after acetic acid induced gastric
ulcers, twelve rats with naturally healed ulcers were killed
before the administration of recombinant human IL-1β
(Genzyme, Boston, MA) to observe the ulcer stage. Since all
ulcers were found to heal completely at 28 weeks after ulcer
induction with acetic acid, twelve animals in each group
were given recombinant human IL-1β (200 µg/kg) intra-
peritoneally according to Watanabe’s model of ulcer
recurrence [26]. Another preliminary study was done to
document the best time point for ulcer recurrence and we
obtained the result that at 48 h after IL-1β injection 100%
of ulcers were recurred, whereas 66.7% ulcer recurred after
24 h of IL-1β injection in our model. Therefore, the animals
were killed 48 h later to evaluate the rate of ulcer recurrence
according to treatment group (Fig. 1). Ulcer specimens were
fixed in 10% buffered formalin or immediately frozen in
liquid nitrogen for hematoxylin-eosin (H&E) staining and
further immunohistochemical staining. Tissues were excised
at ulcer margin and immediately frozen for elucidating their
molecular mechanisms.
Western blot for COX-2, TGF-α, EGF and pS2/TFF1 in
gastric homogenates of gastric ulcers
Pooled gastric mucosa was homogenized in ice-cold
20 mM Tris-HCl buffer, pH 7.5 containing 2 mM EDTA,
0.5 mM EGTA, 300 mM sucrose, 2 mM phenylmethyl
sulfonyl fluoride (PMSF) with a tissue homogenator at 4°C.
Ten microgram of the protein was subjected to electro-
phoresis on an 8% SDS-PAGE gel and transferred onto
PVDF membrane. The blots were blocked with 5% nonfat
dry milk, and then incubated overnight at 4°C with primary
antibodies for HSP 27, HSP 70, or α-tubulin (Santa cruz
Biotech, Santa Cruz, CA), followed by probing with 1:2000
diluted HRP-conjugated secondary antibody. The immuno-
Fig. 1. Experimental protocol for ulcer healing and ulcer recurrence according to group. Group I denotes the group of rats healed
naturally up to 28 weeks after serosal injection of acetic acid, Group II denotes the group of rats treated with 8 weeks of proton
pump inhibitor, intraperitoneal injections of omeprazole, and Group III denotes the group of rats receiving 8 weeks of
gastroprotectant, DA-9601 in pellet diets. After 28 weeks, all rats were administered with intraperitoneal injections of 200 µg/
kg recombinant IL-1β irrespective of group and sacrificed after 48 h later to observe ulcer recurrence. Meanwhile, 12 rats in
each group were killed at 4 weeks after acetic acid injection and the remaining 12 rats in each group were sacrificed at 28 weeks
after acetic acid injection. Preliminary study confirmed that 28 weeks of duration were enough for complete ulcer healing even
without any treatment. The classification of ulcer stage was determined based on the classification of Sakita and Miwa [25] as A
(active) stage, H (healing) stage, and S (scarring) stage.QOUH Feasible only with Gastroprotectant
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complex were detected using ECL detection kit (Ammer-
sham Phamacia Biotec, Uppsala, Sweden). cyclooxygenase-
2 (COX-2), TGF-α, EGF, trefoil peptide (pS2/TFF1),
platelet derived growth factor (PDGF) and vascular endo-
thelial growth factor (VEGF) were measured.
Immunofluorescence staining and Alcian blue staining
The frozen sections were fixed in cold acetone at −20°C
for 5 min and incubated overnight with each 1:100 diluted
antibody, including pS2, EGF, all purchased from Santa
Cruz Biotech. After washing with phosphate-buffered
saline, they were incubated for 30 min with fluorescein
isothiocyanate (FITC)-conjugated anti-rabbit immuno-
globulin (Sigma Chemical Co., Saint Louis, MO) diluted
1:100. Immuno-fluorescence signal was evaluated using a
fluorescence microscope. EGF, TFF1 and mucin were
determined
RT-PCR analysis
Total RNA was isolated from cells with appropriate
treatment using the TRIzol reagent (Life technologies,
Milan, Italy) and 2 µg of total RNA was reverse transcribed
according to the manufacturers’ instructions of M-MLV
Reverse transcriptase (Promega, Madison, WI). The PCR
was performed by using the Premix Ex Taq kit (Takara,
Chiba, Japan) with specific primers as follows: 5'-GAA GTG
TAT TAG GAC GCT GG-3' and 5'-TGT AGA GGC TGT CCA
AGT CT-3' for PDGF, 5'-GTC GTA CGA TGG GTA CTG
CC-3' and 5'-GCG CAG CTT CCA CCA ACG TA-3' for
EGF, 5'-TGC ACC CAC GAC AGA AGG GGA-3' and 5'-
TCA CCG CCT TGG CTT GTC ACA T-3' for VEGF, 5'-TGA
AGG TCG GTG TCA ACG GAT TTG GC-3' and 5'-CAT
GTA GGC CAT GAG GTC CAC CAC-3' for GAPDH.
Enzyme-linked immunosorbent assay for cytokines
Immunoreactive cytokine level of IL-2, tumor necrosis
factor-alpha (TNF-α), and IL-10 was measured in gastric
mucosa of rats by using enzyme-linked immunosorbent
assay (ELISA) kits purchased from R&D Systems Europe
(Abington, U.K.).
Histological examination for quality of ulcer healing
Ulcer specimens were fixed in 10% buffered formalin and
embedded in paraffin. Tissues were sectioned in 4 µm
thickness for H&E staining. Neutral glycoproteins (mucin)
were stained by periodic acid-Schiff. We evaluated the
quality of ulcer healing based on the histological assessment
of epithelial re-consititution 6 months after treatment. Poor
quality of ulcer healing was defined as histological abnor-
malities included dilated gastric glands and pits, reduced
height of granulation tissue and inadequate secretion of
neutral mucin.
Statistical analysis
Results are expressed as the mean ± SD. The data were
analyzed by one-way analysis of variance (ANOVA), and
the statistical significance between groups was determined
by Duncan’s multiple range test. Statistical significance was
accepted with a p<0.05.
Results
Accelerated healing of acetic acids-induced gastric ulcer in
rats treated with gastroprotectant than acid suppressant at 4
weeks after gastric ulcerogenesis
To determine the size and staging of gastric ulcers after
each treatment, animals were killed with an overdose of
ether and their stomachs were removed. Then the stomachs
were pinned to a cork board and then inflated, and the areas
(mm2) of the ulcers were determined and the classification of
ulcer stage was determined based on the classification of
Sakita and Miwa [25]. Twelve rats in each group were
sacrificed at 4 weeks after intragastric acetic acid injection
for assessing the healing status according to group. All
gastric ulcers in Group I and 10 out of 12 in Group II were
still in active stage of gastric ulcer (A stage) at 4 weeks after
acetic acid injections, but, 7 out of 12 rats (58.3%) in Group
III were already in healing stage of gastric ulcer, mostly H2
stage ulcer. As seen in Fig. 2, the ulcer niche was consider-
ably decreased in Group III, of which ulcer base was almost
disappeared reaching to S stage of ulcer in some rats,
suggesting that gastroprotectant treatment imposed rather
accelerated healing process (Fig. 2).
The pooled expressions of TGF-α were significantly
increased in both Group II and III than Group I. The expres-
sions of EGF were considerably increased only in Group III.
Though there was no significant difference in the expression
of either COX-2 or pS2/TFF1 with western blot analysis
(Fig. 4A), the immunohistochemical stainings of EGF and
pS2/TFF1 were significantly increased in Group III. In
detail, prominent gastric glands showing high expressions
of pS2/TFF1 observed in Group III were UACL (ulcer
associated cell lineage), precursor for regenerating gastric
glands (Fig. 4B). The expression of neutral mucin with
Alcian blue staining was apparently increased in drug-
treated groups (Group II and Group II) than naturally
healing group (Fig. 4C).
Significant resistance to ulcer recurrence in group III,
treated with gastroprotectant
Since preliminary study showed that 100% of gastric
ulcers induced by acetic acid injection was healed com-
pletely after 24–28 weeks, converting into S stage of gastric
ulcer and ulcer was recurred approximately 75% after 24
and 100% after 48 h of intraperitoneal injections of 200 µg/
kg of IL-1β, we determined the point of ulcer recurrenceT.Y. Oh et al.
J. Clin. Biochem. Nutr.
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experiment at 28 weeks after acetic acid and the point of
sacrifice at 48 h later after IL-1β injection (Fig. 1).
11 out of 12 rats with scarred gastric ulcer (91.7%) in
Group I were recurred after IL-1β injection and 9 out of 12
rats (75.0%) showed ulcer recurrence in Group II, all
converting to A stage of ulcer after IL-1β injection.
However, only 2 out of 12 (16.7%) showed ulcer recurrence
and the other 10 out of 12 rats remained in S stage gastric
ulcer even after the administration of intraperitoneal IL-1β,
signifying that considerable resistance of ulcer recurrence
Fig. 2. Gastric ulcer stage assessed at 4 weeks after acetic acid according to group. All gastric ulcers of group I and 10 out of 12 in
Group II were still active stage of gastric ulcer, telling that two cases of Group II was healing stage, whereas 7 out of 12 rats
(58.3%) in Group III were found to be healing stage ulcer, mostly H2 stage ulcer. Accelerated healing of gastric ulcer was noted
in group treated with gastroprotectant.
Fig. 3. Ulcer recurrence rates after IL-1β administration according to groups. Since preliminary study showed that 100% healing of
gastric ulcer was noted after 24–28 weeks, converting into S stage of gastric ulcer, and ulcer was recurred after 24–48 h of
intraperitoneal injections of 200 µg/kg of IL-1β, we administered IL-1β to all rats of experimental groups and sacrificed 48 h
later. 11 out of 12 rats with scarred gastric ulcer (91.7%) in Group I were recurred after IL-1β injection and 9 out of 12 rats
(75.0%) showed ulcer recurrence in Group II. However, only 2 out of 12 (16.7%) showed ulcer recurrence and the remaining 10
out of 12 rats remained intact even after the administration of IL-1β, signifying that considerable resistance of ulcer recurrence
was achieved in group treated with gastroprotectant.QOUH Feasible only with Gastroprotectant
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was achieved in group treated with gastroprotectant, DA-
9601 (Fig. 3). Besides of DA-9601, similar resistance to
ulcer recurrence was shown in rats group treated with other
kinds of gastroprotectants like rebamipide and ecabet
sodium; the overall rates of resistance to ulcer recurrence
experiment according to kind of gastroprotectants were 2/12
(16.7%) with DA-9601, 3/12 (25.0%) with rebamipide, and
3/11 (27.2%) with ecabet sodium, respectively.
Histopathological observations before the induction of
ulcer recurrence with IL-1β were quite differed according to
group as seen in Fig. 5, even though all their gross
morphology looks like scarred ulcer. Dilated and distorted
Fig. 4. Western blot of COX-2, TGF-α, EGF, and pS2/TFF1 and immunohistochemical staining of EGF and pS2/TFF1 according to
group (A) Western blot. The pooled expressions of TGF-α were significantly increased in Group II and III than group I and the
expressions of EGF were considerably increased in Group III. There was no significant difference in the expression of either
COX-2 or pS2/TFF1. (B) Immunofluoroscence staining for EGF and pS2/TFF1 at ulcer margin. Immunohistochemical
stainings of EGF and pS2/TFF1 were significantly increased in Group III. Prominent gastric glands showing high expressions
of pS2/TFF1 observed in group III were UACL (ulcer associated cell lineage) (×200 magnification). (C) The change of neutral
mucins at the periphery of acetic acids-induced gastric ulcer with Alcian blue mucin staining. The expression of neutral mucin
with Alcian blue mucin staining was apparently increased in drug-treated groups (Group II and Group II) than natural healing
group (×100 magnification).T.Y. Oh et al.
J. Clin. Biochem. Nutr.
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gastric glands were noted in both Group I (naturally healed)
and Group II (proton pump inhibitor (PPI)-treated group),
whereas normal looking, well restored and remodeled
gastric mucosa was seen in Group III (DA-9601 as gastro-
protectant-treated group). We defined the histological
morphology of Group III after 28 weeks was remodeled
regeneration. Significant infiltrations of inflammatory cells
and denuded mucosal layers were seen after IL-1β injection
in Group I and II, whereas considerably attenuated inflam-
matory response and conserved mucosal layer were seen
in Group III even after IL-1β injection, signifying that
excellent remodeling of regenerated gastric mucosa, hard to
discriminate between intact gastric mucosa and regenerated
gastric mucosa, was achieved in rats treated with gastro-
protectants and might be responsible for resistance to ulcer
recurrence (Fig. 5).
The molecular basis for the resistance to ulcer recurrence in
rats treated with gastroprotectant
The mean levels of IL-2 were significantly lowered in
Group III than Group I and Group II and the mean levels of
TNF-α were significantly decreased only in Group III.
However, there was no significant difference in IL-10 levels
between groups. This result suggested that lesser degrees of
gastric inflammation as seen in histopathology were pro-
voked in rats treated with gastroprotectants, even though
treated with potent inflammatory cytokine, IL-1β (Fig. 6A).
Significantly attenuated expressions of either COX-2 or
nitrotyrosine were noted in rats showing resistance to ulcer
recurrence irrespective of treatment group, suggesting COX-
2 and nitrotyrosine might contribute to ulcer recurrence. The
expressions of HSP 27 were increased in Group III, rats
treated with DA-9601, suggesting the lowered recurrence of
gastric ulcer after IL-1β injection might be partly related to
the cytoprotective effects of molecular chaperone, HSP 27
(Fig. 6B). However, growth factors did not contribute to
ulcer recurrence since no significant difference in the
expressions of EGF, PDGF, and VEGF among either treat-
ment groups or status of gastric ulcer was noted (Fig. 6C).
Discussion
Our current results showed that gastroprotectant was quite
efficient in either accelerating the ulcer healing at the early
phase of ulcer healing or hindering the recurrence of gastric
ulcer after complete ulcer healing, whereas acid suppressant
was somewhat inferior in these aspect of ulcer healing
compared to gastroprotectant. Simply stated, the achieve-
ment of ideal QOUH could only be accomplished with
intervention of the enhancement of gastric defense systems.
Therefore, though acid suppressant is gold standard treat-
ment for gastric ulcer, the anti-secretory agents alone were
Fig. 5. Histopathology of scarred gastric ulcer before and after IL-1β injection according to treatment. Gross observation before IL-1β
injection at 28 weeks after acetic acid induced gastric ulcer showed that all acetic acids-induced gastric ulcers become scarring
stage (S1 or S2 stage) irrespective of group. However, histopathological observations were differed so much according to group.
Dilated and distorted gastric glands were noted in both Group I (naturally healed) and Group II (PPI-treated group), whereas
normal looking restored gastric mucosa was seen in Group III (DA-9601 treated group). Significant infiltrations of inflam-
matory cells and denuded mucosal layers were seen after IL-1β injection in Group I and II, but attenuated inflammatory
response and conserved mucosal layer were seen in Group III, signifying that excellent remodelling of regenerated gastric
mucosa, hard to discriminate between intact gastric mucosa and regenerated gastric mucosa, was achieved in rats treated with
gastroprotectants and might be responsible for resistance to ulcer recurrence after IL-1β injection.QOUH Feasible only with Gastroprotectant
Vol. 42, No. 3, 2008
211
not sufficient for reaching QOUH, necessitating the
combined use of anti-secretory and gastroprotective agent.
We also added the plausible molecular bases for QOUH
achievement with DA-9601 treatment, that was, efficient
remodeling of regenerated gastric mucosa, intervention of
several growth factors, abundant gastric mucins, including
trefoil proteins like pS2/TFF1, and significant suppressions
of inflammatory cytokines like IL-2, TNF-α, COX-2, and
nitrosative stress.
Although we presented the detailed data about DA-9601
treatment, ethanol extracts of Artemisia asiatica [11], among
several gastroprotectants [8–10], which is one of gastro-
protectants prescribed popularly for the treatment of gastritis
and peptic ulcer disease in Korea, possessing actions like
anti-inflammatory, cytoprotective, restorative, and anti-
oxidative actions [11, 21–24], we repeated the same experi-
ment with other gastroprotectants available in clinic like
rebamipide and ecabet sodium, and found that the overall
rates of resistance to ulcer recurrence experiment according
to gastric cytoprotectants were 2/12 (16.7%) with DA-9601,
3/12 (25.0%) with rebamipide, and 3/11 (27.2%) with ecabet
sodium, respectively. Hence, we can’t ignore the principal
role of acid suppressant in the treatment of gastric ulcer, our
suggestions from the current experiment were that in order
to achieve rapid symptom relief, accelerated healing, and
resistance to ulcer relapse, the combined use of acid suppres-
sant and gastroprotectant should be considered. Therefore,
we would like to stress our novel finding that gastro-
protectant treatments were not merely supplementary in the
treatment of gastric diseases, otherwise signifying that
gastroprotectants might be essential and prerequisite for
better healing.
Fig. 6. (A) The changes of mucosal IL-2, TNF-α, and IL-10 according group. The mean levels of IL-2 were significantly lowered in
Group III than Group I and II and the mean levels of TNF-α was significantly decreased only in Group III. However, there was
no significant difference in IL-10 levels between groups. This result suggested that lesser degrees of gastric inflammation were
provoked in rats treated with gastroprotectants. (B, C) Expressions of COX-2, nitrotyrosine, HSP 27, and growth factors
according to group Western blot for COX-2, nitrotyrosine, and HSP27 according to group and status of gastric ulcer. Signifi-
cantly attenuated expressions of either COX-2 or nitrotyrosine were noted in rats showing resistance to ulcer recurrence
irrespective of treatment group, suggesting COX-2 and nitrotyrosine might contribute to ulcer recurrence. The expressions of
HSP 27 were increased in Group III, rats treated with DA-9601, suggesting the lowered recurrence of gastric ulcer after IL-1β
injection might be related to the cytoprotective effects of molecular chaperone, HSP 27. (C) RT-PCR for EGF, PDGF, and
VEGF according group and status of gastric ulcer. No significant difference in the expressions of EGF, PDGF, and VEGF
among either treatment groups or status of gastric ulcer.T.Y. Oh et al.
J. Clin. Biochem. Nutr.
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Since, by definition, an ulcer penetrates through the
muscularis mucosa into the underlying submucosa and
sometimes to the muscularis externae, repair of such damage
requires the complete reestablishment of a connective tissue
and reformation of glandular architecture [27]. The healing
of ulcer is accomplished by filling of the mucosal defect
through the regeneration of gastric glands and ECM to
restore mucosal structure. Therefore, several growth factors
have been implicated in this process by regulating cell func-
tions, such as cell proliferation, migration, differentiation,
secretion, and degradation of ECM since the exogenous
administration of either natural or recombinant analogues of
the growth factors is reported to accelerate the healing
process [28]. Some examples of key growth factors involved
in immediate ulcer repair are heparin, EGF, basic fibroblast
growth factor (bFGF), TNF-α, hepatocyte growth factor
(HGF), TGF-α, TGF-β, and trefoil peptide (TFF). Also, up-
regulation of receptors for some of these growth factors,
such as EGF receptor, has been demonstrated to occur in the
cells lining the ulcer margin. A new cell lineage can be
observed at the ulcer margin that secretes EGF and TFF, so
called ulcer associated cell lineage (UACL) [13, 29].
TFF is a group of small molecule polypeptide and mainly
secreted by gastrointestinal mucous cells. There are three
kinds of TFF found in mammals, which are stomach specific
TFF (pS2/TFF1), spasmolytic polypeptide (SP/TFF2), and
intestinal trefoil peptide (ITF/TFF3) [30], which has the
function of mucosa protection, epithelial restitution, carci-
noma suppression, and apoptosis adjustment [31]. Since the
stimulus for increased epithelial cell proliferation in the
mucosa of ulcer margin is most likely initiated by EGF
and/or TGF-α, the levels of EGF and/or TGF-α are closely
correlated with accelerated healing. Immunohistochemical
studies demonstrated that cells lining dilated gastric glands
at the ulcer margin display an enormous increase in expres-
sion of EGF, EGFR, and TNF-a at the initial stage (1–7 days)
after ulcer induction [7,  13,  15]. Moreover, the gastric
ulceration can induce the development of a novel cell
lineage, which grows from the bases of existing crypts or
glands to form new glands, so called, ulcer associated cell
lineage (UACL). All of these facts can explain how group III
can achieve 58.3% of H stage gastric ulcer with even 4
weeks of gastroprotectant administration (Fig. 2).
In addition to accelerated ulcer healing, another implica-
tion of gastroprotectants in ulcer healing was significant
attenuation of the gastric ulcer recurrence. A rat model of
induction of gastric ulcer recurrence by IL-1β was first
developed by Watanabe T et al. [32], which is useful for
investigating the pathogenesis of gastric ulcer recurrence as
approximately 80–100% of healed ulcer recurs at sites of
scarred mucosa within 48 h after injection of IL-1β. As
seen in Fig. 4, the process of ulcer recurrence has been
known to be neutrophil-dependent, oxidative stress depen-
dent, and also gastric acid engaged. We could find the
plausible mechanisms for resistance to ulcer recurrence in
group III, which were excellent remodeling activity, enrich-
ments of molecular chaperones like heat shock protein 27
(HSP27), significant decreases in inflammatory cytokines
like COX-2, IL-2, and TNF-α, and quenching nitrosative
stress associated with the infiltrations of inflammatory cells
after IL-1β.
Heat shock proteins (HSPs) act as molecular chaperones
and exhibit various functions, including protection against
apoptosis, protease inhibition and cross-linkage to other
proteins. While the induction of HSPs seems to be important
for protection against apoptosis, protease inhibition, re-
folding, and activity of partially denatured proteins, other
reports indicate that their beneficial effect may be especially
important for the later phase of regeneration, when oxidative
stress caused by infiltrating inflammatory cells may oppose
tissue repair [33, 34], signifying that HSP27 induction might
be one of mechanisms lower recurrence of gastric ulcer after
IL-1β in gastroprotectant administration. COX, the key
enzyme for synthesis of PG, exists in two forms (COX-1 and
COX-2). COX-1 is constitutively expressed in the GI tract in
large quantities and has been suggested to maintain mucosal
integrity through continuous generation of PGs, COX-2 is
induced predominantly during inflammation [35]. As seen in
Fig. 5A, the levels of COX-2 were higher in recurrence rats
than resistance to ulcer recurrence irrespective of groups,
suggesting higher COX-2 levels might reflect the more
gastric inflammations with profuse neutrophil infiltrations.
Besides of COX-2 expressions, nitrotyrosine has been
used as a biological marker for the pathogenic consequences
of endogenous exposure to nitric oxide-related compounds
and reactive nitrogen species, reflecting the formation of
peroxynitrite (ONOO−), the oxidative damage of which may
be assessed by the detection of nitrated [36] protein tyrosine
residue (nitrotyrosine). Therefore, these specific markers
carry the risk for either carcinogenesis risk or severe inflam-
matory response [37]. Gastroprotectant showed significant
inhibitory activity against nitrotyrosine formation as seen in
Fig. 6B.
Ulcer healing is a complicated process requiring inter-
action between ECM proteins and the granulation tissue
supplying the connective tissue cells and endothelial cells
and the quality of ulcer repair remains crucial for the
stability of the injured tissue and for preventing recurrence.
Therefore, remodeling may be critical for proper restoration
of gastric glands and wall integrity [28, 38, 39]. Careful
histopathologic inspections of regenerated gastric mucosa
led to us find the very different histology of regenerated
gastric glands between natural healing or acid suppressant
treated groups and gastroprotectant treated group. The
regenerated gastric glands were dilated, distorted, and
variable sized gastric glands in acid suppressant group, butQOUH Feasible only with Gastroprotectant
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well maturated, organized, slender, and similar sized gastric
glands in gastroprotectant treated group, so called achieve-
ment of remodeling during regenerations and restitution.
However, since gastric acid is required for recurrence of
gastric ulcers caused by IL-1β [32], and gastric acid stimu-
lates the inflammatory process in scarred mucosa during
ulcer recurrence, we propose that QOUH could be effi-
ciently achieved with treatment of both acid suppressant
and gastroprotectant. Qualitative maturation with gastro-
protectants in addition to quantitative achievement with acid
suppressants is warranted for ideal and qualified ulcer
healing. In conclusion, our data showed that gastroprotectant
is not a merely supplementary in the treatment of gastric
ulcer for enhancing defense factors, but prerequisite treat-
ment for qualified ulcer healing.
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